Sanford Chodosh Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Grepafloxacin: microbiological properties

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

The changing epidemiology of severe infections in the ICU

Herpes zoster in non-hospitalized children

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

Atypical respiratory pathogens

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Bernard Grenier Clinical Microbiology and Infection

Hydatid disease Clinical Microbiology and Infection

Didier Guillemot, Claude Carbon Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

Human metapneumovirus infection among children in Taiwan: a comparison of clinical manifestations with other virus-associated respiratory tract infections

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Sepsis and neutropenia induced by clozapine

Uncommon opportunistic fungi: new nosocomial threats

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

André Bryskier Clinical Microbiology and Infection

Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study M.R. Berndsen,

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin King A. , Bathgate.

Laboratory diagnosis of Clostridium difficile disease

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

G.R. Davies Clinical Microbiology and Infection

Community-acquired pneumonia: epidemiologic and clinical consideration

Grepafloxacin: pharmacokinetics and tissue penetration

Training in infectious diseases and tropical medicine in Britain

Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women F. Auquer, F. Cordón, E. Gorina, J.C. Caballero,

Vaccinations against respiratory tract infections at Hajj

Fibronectin concentrations in catheter sepsis

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Empiric therapy of bacterial infections in severe neutropenia

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

New patterns of HIV-1 resistance during HAART

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Decision-making in otitis media in children, Part I: epidemiologic data and definitions for a reliable cost-effectiveness analysis Bernard Grenier Clinical.

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

Fernando Baquero, John F

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection Sanford Chodosh Clinical Microbiology and Infection Volume 4, Pages S25-S31 (March 1998) DOI: 10.1111/j.1469-0691.1998.tb00686.x Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 3-5 days post-treatment in the clinically evaluable population. Clinical Microbiology and Infection 1998 4, S25-S31DOI: (10.1111/j.1469-0691.1998.tb00686.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 28-42 days post-treatment in the clinically evaluable population. Clinical Microbiology and Infection 1998 4, S25-S31DOI: (10.1111/j.1469-0691.1998.tb00686.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Clinical success rates with grepafloxacin versus comparator drugs in CAP at 28-42 days post-treatment in the microbiologically and clinically evaluable population. Clinical Microbiology and Infection 1998 4, S25-S31DOI: (10.1111/j.1469-0691.1998.tb00686.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Eradication of Haemophilus influenzae with grepafloxacin versus comparator drugs at 3-5 days post-treatment in the microbiological intent-to-treat population. Clinical Microbiology and Infection 1998 4, S25-S31DOI: (10.1111/j.1469-0691.1998.tb00686.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Eradication of Moraxella catarrhalis with grepafloxacin versus comparator drugs at 3-5 days post-treatment in the microbiological intent-to-treat population. Clinical Microbiology and Infection 1998 4, S25-S31DOI: (10.1111/j.1469-0691.1998.tb00686.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions